Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Account Payables (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Change in Account Payables data on record, last reported at -$1.2 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 50.9% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$825000.0, up 30.32%, while the annual FY2025 figure was -$825000.0, 30.32% up from the prior year.
  • Change in Account Payables reached -$1.2 million in Q4 2025 per TNGX's latest filing, down from -$344000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.5 million in Q3 2022 and bottomed at -$2.8 million in Q2 2024.
  • Average Change in Account Payables over 5 years is -$69250.0, with a median of -$351500.0 recorded in 2022.
  • The widest YoY moves for Change in Account Payables: up 43536.36% in 2021, down 36537.56% in 2021.
  • A 5-year view of Change in Account Payables shows it stood at $365000.0 in 2021, then tumbled by 384.93% to -$1.0 million in 2022, then surged by 91.54% to -$88000.0 in 2023, then crashed by 2748.86% to -$2.5 million in 2024, then soared by 50.9% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.2 million in Q4 2025, -$344000.0 in Q3 2025, and -$880000.0 in Q2 2025.